Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenon Medical (TNON) EBITDA (2021 - 2025)

Tenon Medical has reported EBITDA over the past 5 years, most recently at -$2.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 8.26% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$12.6 million, up 7.86%, while the annual FY2025 figure was -$12.6 million, 7.86% up from the prior year.
  • EBITDA for Q4 2025 was -$2.8 million at Tenon Medical, up from -$3.3 million in the prior quarter.
  • Over five years, EBITDA peaked at -$200000.0 in Q1 2021 and troughed at -$7.8 million in Q4 2022.
  • A 5-year average of -$3.4 million and a median of -$3.2 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 1076.5% in 2022 and later soared 60.72% in 2023.
  • Year by year, EBITDA stood at -$2.9 million in 2021, then crashed by 172.59% to -$7.8 million in 2022, then soared by 60.72% to -$3.1 million in 2023, then dropped by 0.29% to -$3.1 million in 2024, then rose by 8.26% to -$2.8 million in 2025.
  • Business Quant data shows EBITDA for TNON at -$2.8 million in Q4 2025, -$3.3 million in Q3 2025, and -$2.8 million in Q2 2025.